Horizon Discovery specializes in the precision engineering of in vitro human cell lines. Employing its proprietary homologous recombination-based genome-editing platform, Horizon applies this expertise to the field of companion diagnostics by developing isogenic ‘knock-in’ and ‘knock-out’ human cell-based control materials. Horizon’s objective is to help bring standardization and comparability across the existing reagent and associated hard ware platforms using these patient-relevant standards. Ultimately, reducing the variability that exists across platforms, clinical thresholds, extraction protocols and control reagents will improve diagnostic accuracy and clinical outcomes for patients. In addition, Horizon offers custom engineering of isogenic cell lines modelling human genetic diseases and endogenous reporter cell lines, to support the discovery and validation of new biomarkers.